The editorial from the Canadian Journal of Neurological Sciences discusses the challenges and controversies surrounding new therapies for Alzheimer's disease, particularly monoclonal antibodies like aducanumab and lecanemab. The editorial questions the need for major changes in the healthcare system to accommodate these therapies, given their modest clinical effects and potential side effects. It also highlights the complexity of Alzheimer's disease and the need for more detailed responder analyses to determine the effectiveness of these new treatments. The editorial concludes by emphasizing the importance of balancing the costs and benefits of these therapies before implementing widespread changes in healthcare systems.